NASDAQ:BNTC Benitec Biopharma Q3 2026 Earnings Report $9.48 -0.16 (-1.69%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Benitec Biopharma EPS ResultsActual EPS-$0.24Consensus EPS -$0.27Beat/MissBeat by +$0.03One Year Ago EPSN/ABenitec Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$4.55 millionBeat/MissN/AYoY Revenue GrowthN/ABenitec Biopharma Announcement DetailsQuarterQ3 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time8:00AM ETUpcoming EarningsBenitec Biopharma's Q1 2027 earnings is estimated for Monday, September 28, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Benitec Biopharma Earnings HeadlinesBenitec Biopharma (BNTC) to Announce Earnings on MondaySeptember 21, 2026 | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Stock Rating Lowered by Wall Street ZenSeptember 19, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 25 at 1:00 AM | Chaikin Analytics (Ad)Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)September 16, 2026 | theglobeandmail.comBenitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 16, 2026 | americanbankingnews.comWedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform RatingSeptember 15, 2026 | finance.yahoo.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC) Inc. (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells. Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement. BB-301 uses an adeno-associated virus vector to deliver a ddRNAi construct intended to reduce production of the mutant protein associated with OPMD. Benitec traces its origins to Australia, where the company was founded to develop RNA interference therapies, and it now operates as a U.S.-based biotechnology company. Its development activities are focused primarily on advancing BB-301 and its broader ddRNAi platform through clinical and regulatory development.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
